© Springer International Publishing Switzerland 2017Paul M. N. Werker, Joseph Dias, Charles Eaton, Bert Reichert and Wolfgang Wach (eds.)Dupuytren Disease and Related Diseases – The Cutting Edge10.1007/978-3-319-32199-8_57 57. International Clinical Research – The Australian Perspective: A Personal View…
© Springer International Publishing Switzerland 2017Paul M. N. Werker, Joseph Dias, Charles Eaton, Bert Reichert and Wolfgang Wach (eds.)Dupuytren Disease and Related Diseases – The Cutting Edge10.1007/978-3-319-32199-8_55 55. Patient-Rated Outcome Measures and Dupuytren Contracture Joseph J. Dias1 (1) University Hospitals…
© Springer International Publishing Switzerland 2017Paul M. N. Werker, Joseph Dias, Charles Eaton, Bert Reichert and Wolfgang Wach (eds.)Dupuytren Disease and Related Diseases – The Cutting Edge10.1007/978-3-319-32199-8_54 54. Clinical Research: International Collaboration to Execute High-Powered Clinical Trials Marie A. Badalamente1 …
© Springer International Publishing Switzerland 2017Paul M. N. Werker, Joseph Dias, Charles Eaton, Bert Reichert and Wolfgang Wach (eds.)Dupuytren Disease and Related Diseases – The Cutting Edge10.1007/978-3-319-32199-8_53 53. How Should We Fund Basic Research of Dupuytren Disease? Dominic Furniss1 …
© Springer International Publishing Switzerland 2017Paul M. N. Werker, Joseph Dias, Charles Eaton, Bert Reichert and Wolfgang Wach (eds.)Dupuytren Disease and Related Diseases – The Cutting Edge10.1007/978-3-319-32199-8_52 52. The Future of Basic Dupuytren Disease Research David B. O’Gorman1 (1) Departments…
Fig. 45.1 Model of target cells and involved factors. Advanced model of target cells and factors involved in the therapeutic modulation of hyperproliferative/fibrotic benign diseases by a low-dose radiation therapy….
Fig. 13.1 Overview network analysis. Simplified workflow of the network analysis integrating GWAS and transcriptome data to search for disease-specific sub-networks in DD. In the first step SNP-based p-values are…
Fig. 4.1 Number of DC diagnoses by quarter Since the approval of CCH in Q1 2010, the use of CCH has steadily increased from 5 % of all DC procedures…
© Springer International Publishing Switzerland 2017Paul M. N. Werker, Joseph Dias, Charles Eaton, Bert Reichert and Wolfgang Wach (eds.)Dupuytren Disease and Related Diseases – The Cutting Edge10.1007/978-3-319-32199-8_39 39. Is Recurrence After Treatment Predictable? Risk Factors in Dupuytren Disease…
(Cline 1777) It does not appear that Dupuytren met with any mischief when he did the operation in this way……. . I think it would be altogether impossible to escape suppuration…
